Treatment of Stomal Incontinence with Coaptite Injections in Continent Cutaneous Urinary Diversions

Purpose: Catheterizable stomal incontinence in continent cutaneous urinary diversions (CCUDs) is a well-documented complication. There are limited reports of using urethral bulking agents in treating stomal incontinence after CCUD. We discuss our experience using Coaptite, an U.S. Food and Drug Administration (FDA)-approved urethral bulking agent, to treat incontinence following CCUD. Methods: We reviewed 16 patients with CCUDs who underwent Coaptite injections between 2012 and 2024. This included ten right colon reservoirs, four native bladders with augmentation plus catheterizable channel, and two revised neobladders who underwent urethrectomy and addition of catheterizable channel. Coaptite was injected near the efferent limb-reservoir junction. Outcomes were categorized as full continence (FC), improved continence (IC), no improved continence (NIC), or worsened continence (WC). Results: Of the 16 patients, 13 (81%) demonstrated positive outcomes in response to Coaptite injections, with 8 (50%) achieving FC, and 5 (31%) IC, with a mean of 2.25 injections per patient. No patients had WC. Among the patients with right colon reservoirs, 9 of 10 had positive outcomes (8 FC, 1 IC). Among those with native bladders or neobladders, 4 of 6 achieved IC, and none achieved FC. By channel type, 7 of the 9 patients with appendiceal channels had positive outcomes (5 FC, 2 IC), whereas 6 of the 7 patients with ileal channels achieved positive outcomes (3 FC, 3 IC). Conclusion: The majority of patients with CCUD-related incontinence experienced improved continence with Coaptite injections. These results support Coaptite as a minimally invasive treatment option for CCUD-related incontinence.

Authors

Institutions

Publication Details

Journal
Journal of Endourology
Published
2026-11-21
DOI
https://doi.org/10.1177/08927790261508366
Primary Topic
Urinary Bladder and Prostate Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Treatment of Stomal Incontinence with Coaptite Injections in Continent Cutaneous Urinary Diversions

Michael F. Basin, Hooman Djaladat, Siamak Daneshmand, Josh Ku et al.
Journal of Endourology
Urinary Bladder and Prostate Research
article

Treatment of Stomal Incontinence with Coaptite Injections in Continent Cutaneous Urinary Diversions

Michael F. Basin, Hooman Djaladat, Siamak Daneshmand, Josh Ku, Leilei Xia, David A. Ginsberg, Anosh Dadabhoy, Chirag P. Doshi, Adam Peña
article en

Abstract

Purpose: Catheterizable stomal incontinence in continent cutaneous urinary diversions (CCUDs) is a well-documented complication. There are limited reports of using urethral bulking agents in treating stomal incontinence after CCUD. We discuss our experience using Coaptite, an U.S. Food and Drug Administration (FDA)-approved urethral bulking agent, to treat incontinence following CCUD. Methods: We reviewed 16 patients with CCUDs who underwent Coaptite injections between 2012 and 2024. This included ten right colon reservoirs, four native bladders with augmentation plus catheterizable channel, and two revised neobladders who underwent urethrectomy and addition of catheterizable channel. Coaptite was injected near the efferent limb-reservoir junction. Outcomes were categorized as full continence (FC), improved continence (IC), no improved continence (NIC), or worsened continence (WC). Results: Of the 16 patients, 13 (81%) demonstrated positive outcomes in response to Coaptite injections, with 8 (50%) achieving FC, and 5 (31%) IC, with a mean of 2.25 injections per patient. No patients had WC. Among the patients with right colon reservoirs, 9 of 10 had positive outcomes (8 FC, 1 IC). Among those with native bladders or neobladders, 4 of 6 achieved IC, and none achieved FC. By channel type, 7 of the 9 patients with appendiceal channels had positive outcomes (5 FC, 2 IC), whereas 6 of the 7 patients with ileal channels achieved positive outcomes (3 FC, 3 IC). Conclusion: The majority of patients with CCUD-related incontinence experienced improved continence with Coaptite injections. These results support Coaptite as a minimally invasive treatment option for CCUD-related incontinence.

Journal of Endourology
USC Norris Comprehensive Cancer Center (US)
Urinary Bladder and Prostate Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon